Andrew Powers
Back

Andrew Powers

Partner

Toronto
APowers@blg.com
416.367.6135

Expertise

Christine Leigh

Practice Assistant

Toronto
cleigh@blg.com
416.367.6749
416.367.6528

Andrew focuses on corporate and securities matters with an emphasis on corporate finance and mergers and acquisitions.

He regularly acts for public and private companies and investment dealers in a range of acquisitions, dispositions, securities offerings, other corporate transactions and regulatory and compliance matters, with an emphasis on the cannabis sector.

Andrew's corporate finance experience includes advising issuers and investment dealers on public and private offerings of debt and equity securities, both domestically and cross-border, with an emphasis on the cannabis sector.

Andrew is also the Co-Chair of National Cannabis Focus Group.

Experience

  • CanniMed Therapeutics Inc. in its defense of a hostile takeover by Aurora Cannabis, which lead to a friendly $1.3 billion take-over of CanniMed.
  • CanniMed Therapeutics Inc. in its proposed acquisition of Newstrike Inc. by way of a Plan of Arrangement.
  • Wildflower Brands Inc. in its brokered $4.5 million marketed private placement offering of subscription receipts and units.
  • Wildflower Brands Inc. in its $45 million acquisition of City Cannabis Corp., which operates the first licenced dispensary network in Vancouver.
  • The Supreme Cannabis Company, Inc. in its $22 million acquisition of Truverra Inc., a private Canadian cannabis company producing high-quality cannabis extracts.
  • Lexaria Bioscience Corp. in connection with its strategic partnership with Altria Group, Inc. for the development of innovations in oral and reduced-risk nicotine and related products.
  • CanniMed Therapeutics Inc. in its $60 million initial public offering of common shares and listing on the TSX.
  • The underwriters, led by Clarus Securities Inc., in numerous bought deal public offerings of common shares of Aphria Inc., raising aggregate proceeds of approximately $860 million.
  • The agents, led by Clarus Securities Inc.,in the $20 million private placement of convertible debentures of Ionic Brands Inc.
  • The agents, led by Clarus Securities Inc., in the $36 million private placement financing of subscription receipts of The Flowr Corporation in connection with its reverse takeover and contemporaneous listing on the TSX Venture Exchange.
  • The agents, led by Clarus Securities Inc., in the $20 million private placement financing of subscription receipts of Ascent Industries Corp. in connection with its reverse takeover and contemporaneous listing on the Canadian Securities Exchange.
  • The underwriters, led by Clarus Securities Inc., in the $52 million bought deal public offering of common shares of Nuuvera Inc.
  • The agents, led by Clarus Securities Inc., in the $35 million private placement financing of subscription receipts of Liberty Health Sciences Inc. in connection with its reverse takeover and contemporaneous listing on the Canadian Securities Exchange.
  • The underwriters, led by Clarus Securities Inc., in the $23 million bought deal public offering of common shares of Liberty Health Sciences Inc.
  • The agents, led by Clarus Securities Inc., in the $60 million private placement of units of Liberty Health Sciences Inc.
  • The agents, led by Clarus Securities Inc., in the $17.5 million private placement financing of subscription receipts of CannaRoyalty Corp. in connection with its reverse takeover and contemporaneous listing on the Canadian Securities Exchange.
  • The underwriters, led by GMP Securities L.P., in the $43 million bought deal public offering of common shares of The Flowr
  • The underwriters, led by GMP Securities L.P., in the $90 million bought deal public offering of convertible debentures of The Supreme Cannabis Company, Inc.
  • The underwriters, led by Eight Capital, in the $86 million bought deal public offering of units of MedMen Enterprises Inc.
  • Eight Capital, as underwriter, in the $13 million bought deal public offering of common shares of InMed Pharmaceuticals Inc.
  • Eight Capital, as underwriter, in the $27 million bought deal public offering of units of Emerald Health Therapeutics Inc.
  • The underwriters, led by Eight Capital, in the $13.8 million bought deal public offering of units of Emerald Health Therapeutics Inc.
  • The agents, led by Canaccord Genuity Corp., in the $14.5 million private placement financing of convertible debentures of Leef Holdings Inc.
  • The underwriters, led by Canaccord Genuity Corp., in the $120 million bought deal public offering of units of MedMen Enterprises Inc.
  • The agents, led by Canaccord Genuity Corp., in the $20 million private placement financing of special warrants of High Tide Ventures Inc.
  • The agents, led by Canaccord Genuity Corp., in the $11 million private placement financing of convertible debentures of High Tide Ventures Inc.
  • Sandstorm Gold Ltd. in its US$152 million multi-asset stream transaction with Yamana Gold Inc.
  • Blackstone Tactical Opportunities Fund in its US$540 million construction financing package with Orion Mine Finance Group to Pretium Resources Inc.
  • Newcastle Gold Ltd. in its acquisition of Catalyst Copper Corp. for approximately $33 million by way of plan of arrangement.
  • Dominion Diamond Corporation in its acquisition of the diamonds business of BHP Billiton, comprised of its controlling interest in the EKATI Diamond Mine and its diamonds marketing operations in Belgium for approximately $550 million.
  • Chemtrade Logistics Income Fund in its acquisition of Marsulex Inc. for approximately $420 million by way of plan of arrangement and the related $149.5 million financing by way of public offering of subscription receipts.
  • Magna International Inc. in its dual class share capital reorganization by way of plan of arrangement.
  • IBM in its acquisition of Cognos Incorporated for approximately $5 billion in cash by way of plan of arrangement.
  • Telegraph Gold Inc. in its acquisition of the Castle Mountain property from Sprott Resource Lending Corp. and Leucadia National Corporation for approximately $8 million.
  • Castle Mountain Mining Company Limited (formerly Telegraph Gold Inc.) in its amalgamation with Foxpoint Capital Corp., a capital pool company, which constituted Castle Mountain's Qualifying Transaction.
  • The underwriters, led by GMP Securities L.P., in the $130 million bought deal private placement of subscription receipts of Klondex Gold Ltd.
  • The underwriters, led by Scotia Capital Inc., in the $33 million public offering of subscription receipts in connection with the $325 million construction financing package to Lydian International Limited.
  • The underwriters, led by TD Securities Inc., in the $300 million bought deal public offering of common shares of Cobalt27 Capital Corp.
  • The agents, led by Credit Suisse Securities (USA) LLC, in the $200 million private placement of common shares of Cobalt27 Capital Inc.

Beyond Our Walls

Professional Involvement

  • Member, Canadian Bar Association
  • Member, Law Society of Upper Canada
  • Member, Prospectors and Developers Association of Canada

Awards & Recognitions

  • Recognized in the 2021 edition of Lexpert Special Edition: Finance and M&A
  • Recognized in the 2020 edition of Lexpert Special Edition: Agribusiness and Cannabis
  • Recognized in the 2020 and 2021 editions of Best Lawyers in Canada (Cannabis Law).
  • Recognized in the 2020 edition of Lexpert Special Edition on Mining.
  • Recognized in the 2020 edition of The Canadian Legal Lexpert® Directory (Corporate Mid-Market).
  • Recognized in the 2020 edition of The Canadian Legal Lexpert® Directory (Mining).

Bar Admission & Education

  • Ontario, 2005
  • JD, Queen's University, 2004
  • BA (Hons.) in Political Science, University of Ottawa, 1998

This website uses cookies

We use cookies on our website. To learn more about cookies, how we use them on our site and how to change your cookie settings, please view our cookie policy. By continuing to use this site without changing your settings, you consent to our use of cookies in accordance with our cookie policy.

Accept